|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 17, 2017 ) Ganulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts.
Report Highlights
According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2017'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.
The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Respiratory which include indications Rheumatoid Arthritis, Breast Cancer, Melanoma, Solid Tumor, Hepatocellular Carcinoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC) , Pancreatic Cancer, Soft Tissue Sarcoma, Bone Cancer, Chronic Obstructive Pulmonary Disease (COPD) , Colon Carcinoma, Juvenile Myelomonocytic Leukemia (JMML) , Leukemias, Liver Cancer, Lung Adenocarcinoma, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) , Osteoarthritis Pain, Plaque Psoriasis (Psoriasis Vulgaris) , Prostate Cancer, Psoriasis, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Renal Cell Carcinoma and Squamous Cell Carcinoma.
For more information about this report at http://www.reportsweb.com/granulocyte-macrophage-colony-stimulating-factor-pipeline-review-h1-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
- The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834356/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Aduro BioTech Inc
Amgen Inc
BriaCell Therapeutics Corp
Cold Genesys Inc
GlaxoSmithKline Plc
Humabs BioMed SA
KaloBios Pharmaceuticals Inc
Morphotek Inc
Sillajen Biotherapeutics
Takeda Pharmaceutical Company Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834356/discount
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Aduro BioTech Inc, H1 2017
Pipeline by Amgen Inc, H1 2017
Pipeline by BriaCell Therapeutics Corp, H1 2017
Pipeline by Cold Genesys Inc, H1 2017
Pipeline by GlaxoSmithKline Plc, H1 2017
Pipeline by Humabs BioMed SA, H1 2017
Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Pipeline by Morphotek Inc, H1 2017
Pipeline by Sillajen Biotherapeutics, H1 2017
Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1) , H1 2017
Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834356/buy/3500
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
